现代诊断性数字乳腺X线摄影的国家性能基准:来自乳腺癌监测联盟的更新
该研究基于乳腺癌监测联盟六个登记处2007至2013年401548次诊断性数字乳腺X线检查,建立当代性能基准:癌检出率34.7/1000、异常判读率12.6%、活检推荐阳性预测值27.5%、敏感性87.8%、特异性90.5%。以乳房肿块为指征时癌检出率64.5/1000、异常判读率18.7%最高。与屏片时代相比,数字诊断性能异常判读率和癌检出率升高、阳性预测值下降,不足70%的放射科医生PPV2和PPV3在可接受范围内。
要点
- 诊断性数字乳腺X线整体癌检出率34.7/1000,异常判读率12.6%,敏感性87.8%,特异性90.5%。
- 以乳房肿块为指征时癌检出率64.5/1000、异常判读率18.7%,为各指征中最高。
- 活检推荐阳性预测值27.5%、活检执行阳性预测值30.4%,不足70%的放射科医生处于可接受范围。
核心结论
- 这些性能指标可作为国家基准,可能有助于将放射科医生诊断性能的显著差异转化为有针对性的质量改进工作。
研究设计与样本
- 前瞻性收集指征与评估数据并链接州癌症登记处的队列研究,纳入六个乳腺癌监测联盟登记处418名放射科医生、92个放射设施,2007至2013年265360名女性的401548次诊断性数字乳腺X线检查。
诊断标准与关键数值
- 整体癌检出率34.7/1000(95%CI 34.1, 35.2),异常判读率12.6%(95%CI 12.5%, 12.7%),活检推荐阳性预测值27.5%(95%CI 27.1%, 27.9%),活检执行阳性预测值30.4%(95%CI 29.9%, 30.9%),假阴性率4.8/1000(95%CI 4.6, 5.0),敏感性87.8%(95%CI 87.3%, 88.4%),特异性90.5%(95%CI 90.4%, 90.6%)。
临床应用与阅片要点
- 性能指标随诊断指征差异很大:以乳房肿块为指征评估乳腺问题时癌检出率64.5/1000、异常判读率18.7%均为最高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To establish contemporary performance benchmarks for diagnostic digital mammography with use of recent data from the Breast Cancer Surveillance Consortium (BCSC). Materials and Methods Institutional review board approval was obtained for active or passive consenting processes or to obtain a waiver of consent to enroll participants, link data, and perform analyses. Data were obtained from six BCSC registries (418 radiologists, 92 radiology facilities). Mammogram indication and assessments were prospectively collected for women undergoing diagnostic digital mammography and linked with cancer diagnoses from state cancer registries. The study included 401 548 examinations conducted from 2007 to 2013 in 265 360 women. Results Overall diagnostic performance measures were as follows: cancer detection rate, 34.7 per 1000 (95% confidence interval [CI]: 34.1, 35.2); abnormal interpretation rate, 12.6% (95% CI: 12.5%, 12.7%); positive predictive value (PPV) of a biopsy recommendation (PPV2), 27.5% (95% CI: 27.1%, 27.9%); PPV of biopsies performed (PPV3), 30.4% (95% CI: 29.9%, 30.9%); false-negative rate, 4.8 per 1000 (95% CI: 4.6, 5.0); sensitivity, 87.8% (95% CI: 87.3%, 88.4%); and specificity, 90.5% (95% CI: 90.4%, 90.6%). Among cancers detected, 63.4% were stage 0 or 1 cancers, 45.6% were minimal cancers, the mean size of invasive cancers was 21.2 mm, and 69.6% of invasive cancers were node negative. Performance metrics varied widely across diagnostic indications, with cancer detection rate (64.5 per 1000) and abnormal interpretation rate (18.7%) highest for diagnostic mammograms obtained to evaluate a breast problem with a lump. Compared with performance during the screen-film mammography era, diagnostic digital performance showed increased abnormal interpretation and cancer detection rates and decreasing PPVs, with less than 70% of radiologists within acceptable ranges for PPV2 and PPV3. Conclusion These performance measures can serve as national benchmarks that may help transform the marked variation in radiologists' diagnostic performance into targeted quality improvement efforts. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Sprague BL, Arao RF, Miglioretti DL, et al. National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology. 2017. PMID: 28244803. doi:10.1148/radiol.2017161519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。